PEAK6
ABCL icon

PEAK6’s AbCellera Biologics ABCL Stock Holding History

PEAK6’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-136,614
Closed -$602K – 2874
2025
Q2 		$469K Sell
136,614
-31,991
-19% -$79.6K ﹤0.01% 2149
2025
Q1 		$376K Sell
168,605
-31,390
-16% -$90K ﹤0.01% 2187
2024
Q4 		$586K Buy
+199,995
New +$557K ﹤0.01% 2070

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

PEAK6's ABCL Position: Q3 2025 in Review

PEAK6 sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 136,614 shares — an estimated $602K sold.

PEAK6 first reported a position in ABCL in Q4 2024 and held it in 3 quarters. The position peaked at $586K in Q4 2024. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

  • PEAK6 reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
  • PEAK6 sold 136,614 AbCellera Biologics shares in Q3 2025, an estimated $602K.
  • PEAK6 first reported a position in AbCellera Biologics in Q4 2024 and held it in 3 quarters.
  • PEAK6's AbCellera Biologics position peaked at $586K in Q4 2024.
  • 141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.